STOCK TITAN

Revvity to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:

UBS Global Healthcare Conference 2025
Monday, November 10, 2025
8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer

Jefferies 2025 London Healthcare Conference
Tuesday, November 18, 2025
2:00 p.m. GMT – Max Krakowiak

Citi's 2025 Global Healthcare Conference
Tuesday, December 2, 2025
9:00 a.m. ET – Prahlad Singh, president and chief executive officer

Attendees will receive an update on the Company and its strategic priorities during fireside chats.

Live audio webcasts will be available on the Events section of the Company’s website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will be available for at least 30 days.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Investor Relations:

Steve Willoughby

steve.willoughby@revvity.com



Media Relations:

Chet Murray

(781) 462-5126

chet.murray@revvity.com

Source: Revvity

Revvity Inc

NYSE:RVTY

RVTY Rankings

RVTY Latest News

RVTY Latest SEC Filings

RVTY Stock Data

11.06B
115.68M
0.34%
100.5%
5.26%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States
WALTHAM